The U.S. Food and Drug Administration (FDA) has approved Ponvory (ponesimod) as an oral treatment for adults with relapsing forms of multiple sclerosis (MS).
The approval covers clinically isolated syndrome, relapsing-remitting MS (RRMS), and active secondary progressive MS (SPMS). The treatment is taken as a 20 mg tablet, once daily, with or without food.
Ponvory (ponesimod) Approved for Adults With Relapsing Forms of MS (multiplesclerosisnewstoday.com)
The approval covers clinically isolated syndrome, relapsing-remitting MS (RRMS), and active secondary progressive MS (SPMS). The treatment is taken as a 20 mg tablet, once daily, with or without food.
Ponvory (ponesimod) Approved for Adults With Relapsing Forms of MS (multiplesclerosisnewstoday.com)
Comment